Hepatocyte Growth Factor Treatment Ameliorates Diarrhea and Bowel Inflammation in a Rat Model of Inflammatory Bowel Disease

L. Grier Arthur, Marshall Z. Schwartz, Keith A. Kuenzler, Ruth Birbe, Henri Ford, L. G. Arthur

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background/Purpose: Transfection of the HLA-B27 gene into normal Fischer rats induces phenotypic changes similar to inflammatory bowel disease (IBD). This study investigated the benefits of 2 doses of hepatocyte growth factor (HGF) on the manifestations of IBD in this rat model. Methods: Fischer rats and HLA-B27 rats were divided into 4 groups: Fischer rats treated with saline, HLA-B27 rats treated with saline, HGF at 150 μg/kg/d, and HGF at 300 μg/kg/d. HGF or saline was infused for 14 days via an osmotic pump attached to a catheter in the internal jugular vein. After treatment, rats were evaluated for diarrhea and reduction in gross and microscopic bowel inflammation. Statistics were determined using analysis of variance (ANOVA). A Pvalue≤ .05 was considered significant. Results: Administration of HGF at 150 μg/kg/d decreased diarrhea by 40%, gross inflammation by 41%, and microscopic inflammation by 72% (P ≤ 5.05). At 300 μg/kg/d HGF decreased diarrhea by 46%, gross inflammation by 45%, and microscopic inflammation by 54% (P ≤ 5.05). Conclusions: HGF administration reduces the clinical manifestations of IBD in this rat model. Similar effects were seen at both doses of HGF administration, implying that there is a plateau above which further increases in HGF levels provides no added benefit. HGF administration may be clinically useful in the management of IBD.

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalJournal of Pediatric Surgery
Volume39
Issue number2
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Hepatocyte Growth Factor
Inflammatory Bowel Diseases
Diarrhea
Inflammation
HLA-B27 Antigen
Inbred F344 Rats
Jugular Veins
Transfection
Analysis of Variance
Catheters

Keywords

  • Hepatocyte growth factor
  • HLA-B27 rats
  • Inflammatory bowel disease

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Cite this

Hepatocyte Growth Factor Treatment Ameliorates Diarrhea and Bowel Inflammation in a Rat Model of Inflammatory Bowel Disease. / Arthur, L. Grier; Schwartz, Marshall Z.; Kuenzler, Keith A.; Birbe, Ruth; Ford, Henri; Arthur, L. G.

In: Journal of Pediatric Surgery, Vol. 39, No. 2, 01.01.2004, p. 139-143.

Research output: Contribution to journalArticle

Arthur, L. Grier ; Schwartz, Marshall Z. ; Kuenzler, Keith A. ; Birbe, Ruth ; Ford, Henri ; Arthur, L. G. / Hepatocyte Growth Factor Treatment Ameliorates Diarrhea and Bowel Inflammation in a Rat Model of Inflammatory Bowel Disease. In: Journal of Pediatric Surgery. 2004 ; Vol. 39, No. 2. pp. 139-143.
@article{d0d3491b0e084433860308061b3b0825,
title = "Hepatocyte Growth Factor Treatment Ameliorates Diarrhea and Bowel Inflammation in a Rat Model of Inflammatory Bowel Disease",
abstract = "Background/Purpose: Transfection of the HLA-B27 gene into normal Fischer rats induces phenotypic changes similar to inflammatory bowel disease (IBD). This study investigated the benefits of 2 doses of hepatocyte growth factor (HGF) on the manifestations of IBD in this rat model. Methods: Fischer rats and HLA-B27 rats were divided into 4 groups: Fischer rats treated with saline, HLA-B27 rats treated with saline, HGF at 150 μg/kg/d, and HGF at 300 μg/kg/d. HGF or saline was infused for 14 days via an osmotic pump attached to a catheter in the internal jugular vein. After treatment, rats were evaluated for diarrhea and reduction in gross and microscopic bowel inflammation. Statistics were determined using analysis of variance (ANOVA). A Pvalue≤ .05 was considered significant. Results: Administration of HGF at 150 μg/kg/d decreased diarrhea by 40{\%}, gross inflammation by 41{\%}, and microscopic inflammation by 72{\%} (P ≤ 5.05). At 300 μg/kg/d HGF decreased diarrhea by 46{\%}, gross inflammation by 45{\%}, and microscopic inflammation by 54{\%} (P ≤ 5.05). Conclusions: HGF administration reduces the clinical manifestations of IBD in this rat model. Similar effects were seen at both doses of HGF administration, implying that there is a plateau above which further increases in HGF levels provides no added benefit. HGF administration may be clinically useful in the management of IBD.",
keywords = "Hepatocyte growth factor, HLA-B27 rats, Inflammatory bowel disease",
author = "Arthur, {L. Grier} and Schwartz, {Marshall Z.} and Kuenzler, {Keith A.} and Ruth Birbe and Henri Ford and Arthur, {L. G.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.jpedsurg.2003.10.001",
language = "English (US)",
volume = "39",
pages = "139--143",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Hepatocyte Growth Factor Treatment Ameliorates Diarrhea and Bowel Inflammation in a Rat Model of Inflammatory Bowel Disease

AU - Arthur, L. Grier

AU - Schwartz, Marshall Z.

AU - Kuenzler, Keith A.

AU - Birbe, Ruth

AU - Ford, Henri

AU - Arthur, L. G.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Background/Purpose: Transfection of the HLA-B27 gene into normal Fischer rats induces phenotypic changes similar to inflammatory bowel disease (IBD). This study investigated the benefits of 2 doses of hepatocyte growth factor (HGF) on the manifestations of IBD in this rat model. Methods: Fischer rats and HLA-B27 rats were divided into 4 groups: Fischer rats treated with saline, HLA-B27 rats treated with saline, HGF at 150 μg/kg/d, and HGF at 300 μg/kg/d. HGF or saline was infused for 14 days via an osmotic pump attached to a catheter in the internal jugular vein. After treatment, rats were evaluated for diarrhea and reduction in gross and microscopic bowel inflammation. Statistics were determined using analysis of variance (ANOVA). A Pvalue≤ .05 was considered significant. Results: Administration of HGF at 150 μg/kg/d decreased diarrhea by 40%, gross inflammation by 41%, and microscopic inflammation by 72% (P ≤ 5.05). At 300 μg/kg/d HGF decreased diarrhea by 46%, gross inflammation by 45%, and microscopic inflammation by 54% (P ≤ 5.05). Conclusions: HGF administration reduces the clinical manifestations of IBD in this rat model. Similar effects were seen at both doses of HGF administration, implying that there is a plateau above which further increases in HGF levels provides no added benefit. HGF administration may be clinically useful in the management of IBD.

AB - Background/Purpose: Transfection of the HLA-B27 gene into normal Fischer rats induces phenotypic changes similar to inflammatory bowel disease (IBD). This study investigated the benefits of 2 doses of hepatocyte growth factor (HGF) on the manifestations of IBD in this rat model. Methods: Fischer rats and HLA-B27 rats were divided into 4 groups: Fischer rats treated with saline, HLA-B27 rats treated with saline, HGF at 150 μg/kg/d, and HGF at 300 μg/kg/d. HGF or saline was infused for 14 days via an osmotic pump attached to a catheter in the internal jugular vein. After treatment, rats were evaluated for diarrhea and reduction in gross and microscopic bowel inflammation. Statistics were determined using analysis of variance (ANOVA). A Pvalue≤ .05 was considered significant. Results: Administration of HGF at 150 μg/kg/d decreased diarrhea by 40%, gross inflammation by 41%, and microscopic inflammation by 72% (P ≤ 5.05). At 300 μg/kg/d HGF decreased diarrhea by 46%, gross inflammation by 45%, and microscopic inflammation by 54% (P ≤ 5.05). Conclusions: HGF administration reduces the clinical manifestations of IBD in this rat model. Similar effects were seen at both doses of HGF administration, implying that there is a plateau above which further increases in HGF levels provides no added benefit. HGF administration may be clinically useful in the management of IBD.

KW - Hepatocyte growth factor

KW - HLA-B27 rats

KW - Inflammatory bowel disease

UR - http://www.scopus.com/inward/record.url?scp=0742270691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742270691&partnerID=8YFLogxK

U2 - 10.1016/j.jpedsurg.2003.10.001

DO - 10.1016/j.jpedsurg.2003.10.001

M3 - Article

C2 - 14966727

AN - SCOPUS:0742270691

VL - 39

SP - 139

EP - 143

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 2

ER -